Research Analysts’ Weekly Ratings Updates for Oncobiologics (OTLK)
by Sarita Garza · The Markets DailyOncobiologics (NASDAQ: OTLK) recently received a number of ratings updates from brokerages and research firms:
- 1/3/2026 – Oncobiologics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
- 12/29/2025 – Oncobiologics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/22/2025 – Oncobiologics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/22/2025 – Oncobiologics had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a “buy” rating on the stock.
- 12/20/2025 – Oncobiologics was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating.
- 12/8/2025 – Oncobiologics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 12/2/2025 – Oncobiologics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/20/2025 – Oncobiologics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.
Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.